Open AccessRole and mechanisms of action ofEscherichia coliNissle 1917 in the maintenance of remission in ulcerative colitis patients: An update
Author(s) -
Franco Scaldaferri,
Viviana Gerardi,
Francesca Mangiola,
Loris Riccardo Lopetuso,
Marco Pizzoferrato,
Valentina Petito,
Alfredo Papa,
Jovana Stojanovic,
Andrea Poscia,
Giovanni Cammarota,
Antonio Gasbarrini
Publication year - 2016
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v22.i24.5505
Subject(s) - ulcerative colitis , mesalazine , medicine , immunology , probiotic , antibiotics , inflammatory bowel disease , disease , diarrhea , colitis , microbiology and biotechnology , biology , bacteria , genetics
Ulcerative colitis (UC) is a chronic inflammatory disease, whose etiology is still unclear. Its pathogenesis involves an interaction between genetic factors, immune response and the "forgotten organ", Gut Microbiota. Several studies have been conducted to assess the role of antibiotics and probiotics as additional or alternative therapies for Ulcerative Colitis. Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negative strain isolated in 1917 by Alfred Nissle and it is the active component of microbial drug Mutaflor(®) (Ardeypharm GmbH, Herdecke, Germany and EcN, Cadigroup, In Italy) used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular disease and UC. It is the only probiotic recommended in ECCO guidelines as effective alternative to mesalazine in maintenance of remission in UC patients. In this review we propose an update on the role of EcN 1917 in maintenance of remission in UC patients, including data about efficacy and safety. Further studies may be helpful for this subject to further the full use of potential of EcN.